Chemotherapy for highly advanced hepatocellular carcinoma

K. Tanikawa
DOI: https://doi.org/10.1046/j.1440-1746.2001.02455.x
2001-04-01
Journal of Gastroenterology and Hepatology
Abstract:year survivial by using the Kaplan–Meier method in 77 patients with advanced HCC (mostly at IV stage) was 56, 28 and 10%, respectively, and no difference in survival was noted between patients with or without portal tumor thrombi. It was also concluded that this therapy is, however, should not be used for patients with poor liver function. a-Interferon is also administered with this combination therapy with relatively good results. However, a transcatheter arterial infusion technique needs some skill to perform, and in many countries this therapy could not be carried out as a popular therapeutic modality. In such circumstances, systemic chemotherapy, either oral or intravenous, is the only possible therapeutic modality to be easily carried out for highly advanced HCC at present. Unfortunately, however, no proven systemic chemotherapy has been developed because no trials have yet been carried out. The study of oral administration of enteric-coated tegafur/uracil for advanced stage IV-A HCC by Ishikawa et al. is encouraging because of significantly prolonged patient survival. However, further trials are needed, including an increased number of patients for the study and comparative randomized trials with other similar agents. At present, chemotherapy seems to be used to treat patients with highly advanced HCC if the patient’s liver function is well preserved and various prospective randomized clinical trials of chemotherapy for HCC are urgently needed.
What problem does this paper attempt to address?